Overall rank by patents
#27,197
Across all tracked assignees
USPTO PatentsView assignee record - 10 granted patents across 6 technology areas, active 2016–2019. Filing-trend and competitive-moat analysis cross-referenced to USPTO Patent Public Search. Primary class: C07F (ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM).
The verdict
Quadriga holds 10 US patents across 6 technology areas, rank #27,197 of 50,000 tracked assignees.
Quadriga Biosciences, Inc. has been granted 10 US utility patents between 2016 and 2019, placing Quadriga Biosciences, Inc. at rank #27,197 across all assignees tracked by PlainPatent. This portfolio spans 6 distinct Cooperative Patent Classification (CPC) subclasses, averaging 21.5 claims per patent with primary concentration in C07F (ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM). As a US Corporation, Quadriga Biosciences, Inc. is one of the more focused assignees in the PatentsView dataset. By volume, Quadriga sits between QILU University OF Technology (shandong Academy OF Sciences) (10 patents, rank #27,193) and Quanticel Pharmaceuticals, Inc. (10 patents, rank #27,201) - the closest US assignees by grant volume. The composite Innovation Score of 29.8/100 blends portfolio volume, filing velocity, technology breadth, and claim depth into a single comparable measure drawn directly from USPTO PatentsView records.
Filing cadence tells the strategic story. Between 2020 and 2025 the company received 0 grants, compared with 10 in the 2015–2019 window, a -100% shift in five-year velocity. A cooling filing rate may reflect portfolio consolidation, shifting priorities, or reduced R&D throughput. The US Corporation classification further shapes interpretation, since corporate, government, and individual filers pursue patents for materially different reasons.
Claim depth and technology breadth together indicate competitive posture. Quadriga Biosciences, Inc.'s 21.5 average claims per patent reflects complex, broadly scoped inventions that are difficult for competitors to design around, while concentration in 6 subclasses points to a focused technical program. Combined with portfolio volume, these signals let analysts, investors, and licensing professionals benchmark Quadriga Biosciences, Inc. against peers pursuing similar technology classes.
Granted US patents 2015–2025 versus its nearest-ranked assignees by volume, this company marked ◀
QILU UNIVERSITY OF TECHNOLOGY (SHANDONG ACADEMY OF SCIENCES)
10 patents
QINGDAO INSTITUTE OF BIOENERGY AND BIOPROCESS TECHNOLOGY, CHINESE ACADEMY OF SCIENCES
10 patents
QINGHAI INSTITUTE OF SALT LAKES, CHINESE ACADEMY OF SCIENCES
10 patents
QOSOUND, INC.
10 patents
QUALIPAC
10 patents
QUANTALRF AG
10 patents
QUANTEX PATENTS LIMITED
10 patents
QUANTICEL PHARMACEUTICALS, INC.
10 patents
QUADRIGA BIOSCIENCES, INC.
10 patents
What this shows Quadriga holds 10 patents at rank #27,197, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.
By rank, the assignees closest to #27,197 in granted patent volume.
Other assignees with the most granted patents in Quadriga's primary technology class.
Quadriga's Innovation Score vs. every tracked assignee
Composite of portfolio volume, filing velocity, technology breadth, and claim depth (0–100)
30 Top 68% higher than 32% of 50,000 US assignees
Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.
Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025
Teal-shaded recent years (2020–present) versus the 2016–2019 baseline. Full figures in the table below.
| Year | Patents Granted | Share of Period |
|---|---|---|
| 2016 | 2 | 20.0% |
| 2017 | 2 | 20.0% |
| 2018 | 4 | 40.0% |
| 2019 | 2 | 20.0% |
Top 6 of 6 technology areas
Overall rank by patents
#27,197
Across all tracked assignees
29.8 out of 100
How to use this portfolio
Quadriga's 10 grants land it in the top 68% by Innovation Score, but volume alone doesn't tell you where the strength sits.
Patent counts and the Innovation Score measure patenting activity, not commercial success or the legal strength of any patent. Many patents are filed defensively. Verify the status of an individual patent against official USPTO records.
Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.